论文部分内容阅读
目的探讨自体DC-CIK细胞对三阴性乳腺癌患者术后免疫功能的影响。方法选取2012年1月至2014年2月间四川省岳池县人民医院收治的48例行乳腺癌改良根治术的三阴性乳腺癌患者,采用随机数表法分为研究组和对照组,每组24例。研究组患者在辅助化疗基础上予以自体DC-CIK细胞治疗,对照组患者予以辅助化疗,比较两组患者治疗前后肿瘤标志物、外周血T淋巴细胞亚群、免疫功能相关细胞因子水平、生存率及不良反应发生率。结果对照组患者生存率为75.0%,低于研究组患者的95.8%,差异有统计学意义(P<0.05)。与治疗前比较,两组患者治疗后血清CEA、CA125、CA153和CK19水平均降低,且研究组患者治疗后水平均低于对照组患者,差异均有统计学意义(均P<0.05)。治疗后,与治疗前比较,研究组患者CD3~+、CD3~+/CD4~+、CD3~+/CD8~+、CD4~+/CD8~+、NK细胞、血清肿瘤坏死因子-α(TNF-α)、干扰素-γ(IFN-γ)和白介素-2(IL-2)水平均升高,对照组患者均降低,且两组比较,差异均有统计学意义(均P<0.05)。两组患者各不良反应发生率比较,差异无统计学意义(P>0.05)。结论自体DC-CIK细胞能有效改善三阴性乳腺癌患者术后免疫功能,降低血清肿瘤标志物水平,提高生存率,且安全性较高。
Objective To investigate the effect of autologous DC-CIK cells on immune function in patients with triple-negative breast cancer. Methods Forty-eight patients with triple-negative breast cancer who underwent modified radical mastectomy in Yuechi County People’s Hospital of Sichuan Province from January 2012 to February 2014 were divided into study group and control group by random number table Group of 24 cases. Patients in the study group were treated with autologous DC-CIK cells on the basis of adjuvant chemotherapy, and patients in the control group were given adjuvant chemotherapy. Tumor markers, peripheral blood T lymphocyte subsets, immune function-related cytokines and survival rates were compared between the two groups And the incidence of adverse reactions. Results The survival rate of the control group was 75.0%, which was lower than 95.8% of the study group, the difference was statistically significant (P <0.05). Compared with those before treatment, the levels of CEA, CA125, CA153 and CK19 in both groups decreased after treatment, and the levels in the study group were lower than those in the control group after treatment (all P <0.05). After treatment, the levels of CD3 +, CD3 + / CD4 +, CD3 + / CD8 +, CD4 + / CD8 +, NK cells, serum tumor necrosis factor-α α, IFN-γ and IL-2 in control group were significantly lower than those in control group (all P <0.05) . There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). Conclusions Autologous DC-CIK cells can effectively improve the immune function, reduce the level of serum tumor markers and improve the survival rate of patients with triple-negative breast cancer, and have higher safety.